Post

New research · Hematology
Transplantation and cellular therapy · 23h
Cohort studyTransplantation and cellular therapy · 2026

Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell Therapy: Clinical Characteristics and Impact on Mortality.

Hadeel Jazieh, Abedalrahman Almashayekh, J Curran Henson … Nishank Jain
Read paper
HematologyCohort study

Acute kidney injury is associated with increased mortality in CAR-T therapy recipients.

Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell Therapy: Clinical Characteristics and Impact on Mortality.

Hadeel Jazieh et al. · Transplantation and cellular therapy · 2026
Background

Chimeric antigen receptor T-cell (CAR-T) therapy is a breakthrough in hematologic malignancies but carries risks, including acute kidney injury (AKI).

Methods

This retrospective study analyzed 186 patients treated with CAR-T therapy, assessing AKI incidence, timing, severity, and associated risk factors within 100 days post-infusion of CAR-T product.

n = 186 patients
Results

sudden kidney damage meant over twice the risk of death for CAR-T recipients

HR 2.59 (95% CI 1.33 to 5.04)
null = 11.335.04
CI excludes the null - significant
More results

Among 186 patients (103 with multiple myeloma (MM), 75 with non-Hodgkin Lymphoma (NHL), and 8 with leukemia), 34% developed AKI (95% CI: 27%-40.7%) with similar incidence by cancer type.

Overall CRS incidence was 82.8% (95% CI: 76.7% to 87.5%) , and 35.1% had AKI although no statistical significance found when compared to those without CRS.

More results

Higher grades of CRS had higher incidence of AKI (Grade 1 = 33.9%; Grade 2 = 37.9%, Grade 3 = 42.9%, P = 0.83) Most AKI episodes were Grade 1 (69.8%) and reversible; 71.4% recovered baseline kidney function, while 28.6% did not, two died within 100 days, 1 required dialysis.

“
Conclusion · 1 of 2

AKI is a frequent and early complication of CAR-T therapy, particularly among African American patients, older individuals, those with CKD and prior history of AKI.

Conclusion · 2 of 2

While most cases are mild and reversible, identifying high-risk patients may enhance monitoring, supportive care, and early intervention.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
30% higher risk
increased risk of new low blood cell counts per 0.1 g/L C3 decrease
Cohort Study
55.9% vs. 68.1%
Diabetic patients had lower major molecular response at 12 months (55.9% vs 68.1%).
Study
92.3%
Share of treated patients whose lymphoma shrank or cleared after treatment
Cohort Study
49%
Nearly half of patients had problems 30 days after spleen removal for blood cancer
Cohort Study
OR 3.95
flexible sigmoidoscopy makes it almost 4 times more likely to find gastrointestinal GvHD
Cohort Study
OR 3.8
Each additional low lab value associated with 3.8 times higher odds of Multisystem Inflammatory Syndrome in Children.
Cohort Study
adjusted hazard ratio 1.917
Patients with leukoerythroblastosis had a 1.9-fold higher hazard of 90-day death.
Guideline
“By integrating international evidence with local circumstances, this document aims to provide Korean clinicians with practical, upto-date guidance to enhance the routine care of patients with TTP.”